Background: Giardia lamblia is a major cause of diarrheal disease among children and adults with a worldwide distribution. With respect to the wide usage of metronidazole for multiple types of infection and risk of drug resistance as well as its side effects, initiation of new therapies seems inevitable. We attempted to compare the therapeutic effects of albendazole with metronidazole in patients with giardiasis.Materials and methods: Having completed an informed consent, 120documented cases of giardiasis, residing in Hamadan, were assigned randomly in two equal groups. The first and second groups received albendazole (400 mg daily as single dose, for 5 days) and metronidazole (250 mg, 3 times a day, for 5 days) respectively. A parasitologist who was blind to the type of therapy, assessed the trophozoites in the samples and check all iodine-stained wet stool preparations before and after the therapeutic intervention. Data analysis was performed using SPSS 9.01 (SPSS Inc. Chicago, IL, USA) using chi square and independent student t tests. Type 1and 2 errors were considered as 0.05 and 0.2 respectively.Results: After the whole course of the therapy, in 6 (10 %) patients of the first group and 14 patients from the second group, failure of treatment was seen and a significant difference between the two groups was found (p<0.05). Response to the therapy was observed in 54(90%) and 46 (76.7%) of patients of the first and second group, respectively (p<0.05). Drug side effects were more likely reported in metronidazole group. Conclusion: Albendazole is a quite safe and effective drug for the treatment of giardiasis and can be easily used in the treatment of giardiasis.